The United Kingdom and the United States have reached a significant trade agreement that will keep no tariffs on British drug exports going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase funding on medicines through the public health system. This move secures that duties on these vital exports will remain at nothing for a period of 36 months.
This deal is in response to previous warnings to hike duties on branded pharmaceutical products, with potential rates floated as high as 100%.
"This agreement with the UK reinforces the international landscape for new treatments and establishes long-overdue balance to American-British medicine commerce," an announcement said.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's largest export categories to the United States, which is by far the biggest buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of the third quarter, the UK sold drugs valued at £11.1bn to the US. This value made up 17.4% of all goods exports in that timeframe.
"This guarantee secures employment, increases investment and sets the stage for the UK to become a international leader for life sciences," a minister commented.
Specific NHS Changes
The pact involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds topped twenty percent.
Broader Context
The deal follows a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were exacerbated by assertions that US consumers were charged several times more for the same drugs than people in the other developed nations.
Recently, several significant manufacturing plans in the UK have been halted or abandoned, while substantial investments have been announced toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a share of its overall budget over the past decade.
